Product Information
RYVENT 6 MG TABLET is a brand (anda) product labeled by CarWin Pharmaceutical Associates LLC, priced at $8.1167 per EA under NDC 15370013010. Its NADAC has been published 374 times since Dec 19, 2018.
FDA first approved this application on May 31, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the carbinoxamine maleate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
6 mg/1
Manufacturer
CarWin Pharmaceutical Associates LLCNDC
15370013010
Classification
Brand (ANDA)
Dosage Form
TABLET
Route
ORAL
Effective Date
2/19/2025
Active Ingredients
CARBINOXAMINE MALEATEApproval Type
Generic (ANDA)
FDA Application
ANDA207484FDA Approved
5/31/2016
TE Code
AB
On Market Since
2/17/2017
Pharmacological Classes
Price Statistics
The NADAC for RYVENT 6 MG TABLET has been published 374 times since Dec 19, 2018, and over the history we have for it it has risen 94.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.1167 per EA |
|---|---|
| All-time high | $8.1167 (Feb 11, 2026) |
| All-time low | $4.1660 (Dec 19, 2018) |
| 52-week high | $8.1167 |
| 52-week low | $8.1167 |
| Median price | $6.4075 |
| Average price | $6.3806 |
| Largest weekly change | +9.9% (Jan 22, 2020) |
| Weeks tracked | 374 |
| Tracking since | Dec 19, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
+9.6%
5Y
+39.2%
All
+94.8%
Last surveyed Feb 11, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the carbinoxamine maleate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
CarWin Pharmaceutical Associates LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
carbinoxamine maleate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RYVENT 6 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RYVENT 6 MG TABLET, manufactured by CarWin Pharmaceutical Associates LLC, is $8.1167 per EA (NDC 15370013010), effective Feb 11, 2026.
How has the price of RYVENT 6 MG TABLET changed over time?
Over the history we have for it, the NADAC for RYVENT 6 MG TABLET has risen 94.8%. It has been tracked across 374 weekly CMS publications since Dec 19, 2018.
What are the highest and lowest recorded NADAC prices for RYVENT 6 MG TABLET?
Since Dec 19, 2018, the NADAC for RYVENT 6 MG TABLET has ranged from a low of $4.1660 (Dec 19, 2018) to a high of $8.1167 (Feb 11, 2026), with a median of $6.4075 per EA.
Are there cheaper alternatives to RYVENT 6 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of RYVENT 6 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RYVENT 6 MG TABLET?
RYVENT 6 MG TABLET (NDC 15370013010) is labeled by CarWin Pharmaceutical Associates LLC, and CMS classifies it as a brand (anda) product.